Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VYD222 in healthy adult participants
NCT05791318Phase 1Completed
- Sponsor
- Invivyd
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of pemivibart in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Invivyd. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 Months. Started Mar 2023; status: completed.
02
Drugs
pemivibart
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05791318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05791318.